RxDoctor Payments Data

Susan Bailey, NP

Family · Glendale, AZNPI 1164892394

Payments from drug & device makers

$1,905in general payments, 2019–2025

Across 108 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Hikma Pharmaceuticals USA$151
  • Vertos Medical, Inc.$139
  • Spinal Simplicity, LLC$133
  • Almatica Pharma LLC$132
  • AbbVie$122
  • plus $205 from 9 others

What the payments were for

  • Food & beverage$1,78394%
  • Education$1226%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,905 in reported general payments places this provider in the 80th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$33,811
Medicare patients
119
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate24$9,807
Xtampza ErOxycodone Myristate14$6,551
Lidocaine-PrilocaineLidocaine/Prilocaine23$5,693
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen143$5,266
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl27$4,329
Oxycodone Hcl198$3,889
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen168$3,468
Buprenorphine14$2,015
Gabapentin179$2,011
Morphine Sulfate ErMorphine Sulfate67$1,498
Morphine Sulfate43$1,330
Naloxone Hcl24$1,316
Cyclobenzaprine Hcl95$1,297
Lidocaine15$1,164
Tramadol Hcl ErTramadol Hcl12$980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$16$9,80724 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Morphine Sulfate$151$7,67484 claims
Collegium Pharmaceutical, Inc.Xtampza Er$28$6,55114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,119 family providers in Arizona.

Other family in Glendale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →